[Assessment of the quality of oral anticoagulation management in patients admitted to Amiens University Hospital].
BACKGROUND
Excessive or insufficient anticoagulation therapy and its associated risks are of major concern in patients receiving oral anticoagulants. Such complications can be avoided by more rigorous management.


OBJECTIVE
The aim of our study was to evaluate those patients receiving oral anticoagulant therapy on the day of hospitalisation among all patients admitted to the Amiens University Hospital during 14 days.


METHODS
We evaluated the quality of management of the treatment in these patients, taking into account the international normalised ratio (INR), as well as important parameters such as the summary of the product characteristics (SPCs), drug interactions, and the level of knowledge of anticoagulant treatment by the patients themselves (questionnaire).


RESULTS
Of the 2498 adult patients hospitalised, 86 patients (30 female and 56 male aged between 26 and 95 years [mean 70 years]) treated with oral anticoagulants were evaluated. At admission, seven cases of haemorrhage and two of thrombosis were registered. One drug-related death occurred and one patient had sequelae. In 17.5% of the cases, the prescription was not fully in agreement with the SPCs. This percentage increased to 67% for patients with adverse effects. In 41% of the patients, the INR was outside the therapeutic zone. The dosage regimen was too complex in 11% of cases. Six drug combinations were labelled as not recommended in the SPCs: four with aspirin <3 g/day and two with nonsteroidal anti-inflammatory drugs. The analysis of questionnaires showed that patients had insufficient knowledge of their treatment: only 16 of 66 knew the risks resulting from overdose or an insufficient dose of the anticoagulant drug, 25 of 66 knew that anticoagulation induced by the treatment can be influenced by food, 10 of 66 knew the therapeutic range of the INR appropriate for them, and 8 of 66 knew that intramuscular injections were prohibited.


CONCLUSIONS
These data confirm that anticoagulant treatment needs to be more strictly controlled in order to avoid adverse effects. Risks are probably underestimated by physicians. Information given to patients seems insufficient or unsuitable (too complex).
Gras-Champel
Valérie
V
Centre Regional de Pharmacovigilance, Service de Pharmacologie Clinique, Amiens, France.
Voyer
Annelise
A
Lematte
Céline
C
Pakula
Pauline
P
Roussel
Bertrand
B
Lefrère
Jean-Jacques
JJ
Andréjak
Michel
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005602:France; D006470:Hemorrhage / Q000188:drug therapy; D006785:Hospitals, University; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011785:Quality Assurance, Health Care; D011795:Surveys and Questionnaires; D013927:Thrombosis / Q000188:drug therapy; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K